

EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma

Standards and Guidelines

Digestive Oncology

Hepatobiliary

April 19, 2023

Intrahepatic cholangiocarcinoma is the second most common primary liver cancer with increasing global incidence, prompting ILCA and EASL to commission dedicated evidence-based guidelines for its diagnosis, prognosis, and treatment.

KEY POINTS

- Intrahepatic cholangiocarcinoma develops inside the liver between bile ductules and the second-order bile ducts and is associated with alarming mortality rates due to silent presentation, late diagnosis, aggressive nature, and treatment resistance
- The disease demonstrates high heterogeneity at clinical, genomic, epigenetic, and molecular levels, which often precludes successful management
- Recent progress has been made in molecular characterisation, surgical management, and targeted therapy
- International experts have been commissioned to draft evidence-based guidelines for physicians involved in diagnostic, prognostic, and therapeutic management of intrahepatic cholangiocarcinoma as a distinct entity within the cholangiocarcinoma family

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/9c17444e-3de5-11ef-92e6-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.